Cajun Seasoning Market Analysis and Forecast to 2030 Featuring Profiles of Royal Nut Company, McCormick & Company, The Kraft Heinz Company, Olam Group, ROSE HILL Foods - A $423.6 Million Global Opportunity
May 02, 2024 09:45 ET
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Global Cajun Seasoning Market Size, Share & Trends Analysis Report By Sales Channel (Store Based Retailing, and Non Store Based Retail), By...
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
May 02, 2024 07:30 ET
|
BridgeBio Pharma, Inc.
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3...
Theratechnologies présentera des données à long terme sur l’efficacité, l’innocuité et la pharmacocinétique de l’utilisation du TH1902 (sudocétaxel zendusortide) dans les tumeurs solides lors du Congrès 2024 de l’ASCO
May 02, 2024 07:30 ET
|
Theratechnologies
Dévoilement de données à long terme des parties 1 et 2 de l’essai clinique de phase I portant sur le sudocétaxel zendusortide dans les tumeurs solidesLa partie 3 de la phase I de l’essai sur le cancer...
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
May 02, 2024 07:30 ET
|
Theratechnologies
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing MONTREAL,...
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
May 02, 2024 07:00 ET
|
BridgeBio Pharma, Inc.
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington...
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
May 01, 2024 07:00 ET
|
Beyond Air™
HAMILTON, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for...
Douglas Dynamics Reports First Quarter 2024 Results
April 29, 2024 18:00 ET
|
Douglas Dynamics, Inc.
Produced Significantly Improved Results Compared to 1Q23;Solutions Segment Continues to Deliver Strong Top- and Bottom-Line Growth First Quarter 2024 Highlights*: Net...
Ethnic Food Market To Reach USD 108.2 Billion By 2032, Says DataHorizzon Research
April 26, 2024 05:30 ET
|
DataHorizzon Research
Fort Collins, Colorado, April 26, 2024 (GLOBE NEWSWIRE) -- The high demand for ethnic cuisine will drive the market demand in the coming years. The demand for ethnic cuisine is poised to soar in...
Y-mAbs to Present at 2024 ASCO Annual Meeting
April 25, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
April 25, 2024 08:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...